Kairos Pharma, Ltd. (AMEX:KAPA) stock climbed 4.1% in premarket trading on Tuesday after the clinical-stage biopharmaceutical company announced it has been selected to present at the upcoming European Society for Medical Oncology (ESMO) Congress in Berlin, Germany, scheduled for October 2025.
At the conference, Kairos will present interim Phase 2 results from its ongoing trial evaluating ENV105 (carotuximab) — a first-in-class CD105 antagonist — in combination with apalutamide for patients with metastatic castration-resistant prostate cancer (mCRPC) who have experienced progression after hormone therapy.
The randomized Phase 2 trial aims to enroll 100 men across three leading U.S. cancer centers: Cedars-Sinai Medical Center, City of Hope, and the Huntsman Cancer Institute at the University of Utah. Participants are divided into two arms — one receiving apalutamide monotherapy and the other treated with apalutamide plus ENV105.
“The data we will be presenting at the 2025 ESMO Congress demonstrates encouraging safety and early efficacy findings from our Phase 2 trial,” said Neil Bhowmick, PhD, Chief Scientific Officer of Kairos Pharma. “This is an important venue for us to share the therapeutic potential of ENV105 for patients with few remaining treatment options after hormone therapy resistance develops.”
Prostate cancer continues to pose a major global health burden, with more than one million new cases diagnosed each year in the United States alone. The emergence of resistance to androgen-targeted therapies remains a critical challenge in treating mCRPC, underscoring the urgent need for novel therapeutic strategies such as ENV105.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.